We are live on
!
Find out more
SAM
Senzar Asset Management Portfolio holdings
AUM
$34.7M
1-Year Est. Return
0.56%
This Fund
S&P 500
This Quarter
Est. Return
+14.96%
1 Year Est. Return
+0.56%
3 Year Est. Return
-0.75%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$410M
AUM Growth
+$69.1M
(+20%)
Cap. Flow
+$36M
Cap. Flow
% of AUM
8.78%
Top 10 Holdings %
Top 10 Hldgs %
64.9%
Holding
47
New
15
Increased
13
Reduced
5
Closed
14
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
STJ
St Jude Medical
STJ
|
+$48.8M |
| 2 |
KND
Kindred Healthcare
KND
|
+$33.2M |
| 3 |
Eli Lilly
LLY
|
+$21.8M |
| 4 |
Labcorp
LH
|
+$20.2M |
| 5 |
MiMedx Group
MDXG
|
+$19.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Viatris
VTRS
|
+$26.1M |
| 2 |
Community Health Systems
CYH
|
+$23.5M |
| 3 |
Bausch Health
BHC
|
+$21.5M |
| 4 |
AGN
Allergan plc
AGN
|
+$18.4M |
| 5 |
Biogen
BIIB
|
+$12.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 83.04% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
STJ
1
DELISTED
St Jude Medical
STJ
| $48M | 11.69% |
+733,600
| New | +$48.8M |
|
|
KND
2
DELISTED
Kindred Healthcare
KND
| $38.9M | 9.49% |
+1,636,600
| New | +$33.2M |
|
3
Teva Pharmaceuticals
TEVA
$36B
| $34.3M | 8.37% |
551,197
+320,300
| +139% | +$18.6M |
|
|
NVRO
4
DELISTED
NEVRO CORP.
NVRO
| $25.1M | 6.12% |
523,736
+311,233
| +146% | +$13.5M |
|
5
Sanofi
SNY
$104B
| $23.7M | 5.78% |
479,412
-225,700
| -32% | -$10.8M |
|
|
6
Eli Lilly
LLY
$1.05T
| $22.3M | 5.43% |
+306,500
| New | +$21.8M |
|
|
7
MiMedx Group
MDXG
$621M
| $21.9M | 5.33% |
+2,102,059
| New | +$19.7M |
|
|
8
Labcorp
LH
$23.8B
| $21.3M | 5.19% |
+196,716
| New | +$20.2M |
|
|
CNCE
9
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
| $16.9M | 4.12% |
1,116,100
+249,900
| +29% | +$3.49M |
|
|
ELOS
10
DELISTED
Syneron Medical Ltd
ELOS
| $13.9M | 3.39% |
1,122,900
+821,800
| +273% | +$9.1M |
|
11
Orthofix Medical
OFIX
$443M
| $12.3M | 3% |
343,201
+36,303
| +12% | +$1.14M |
|
12
Travere Therapeutics
TVTX
$5.2B
| $11.5M | 2.8% |
478,900
-156,800
| -25% | -$2.39M |
|
|
RCPT
13
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
| $11.3M | 2.75% |
+68,400
| New | +$8.66M |
|
14
Insmed
INSM
$23.2B
| $11.2M | 2.73% |
539,107
-138,493
| -20% | -$2.44M |
|
|
MNTA
15
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
| $10.6M | 2.57% |
695,016
+111,300
| +19% | +$1.45M |
|
|
XNPT
16
DELISTED
XENOPORT, INC.
XNPT
| $10.4M | 2.53% |
1,456,900
+368,200
| +34% | +$2.86M |
|
|
SGNT
17
DELISTED
SAGENT PHARMACEUTICALS INC COM STK (DE)
SGNT
| $9.71M | 2.37% |
417,692
+149,392
| +56% | +$3.95M |
|
|
PMC
18
DELISTED
PharMerica Corporation
PMC
| $7.8M | 1.9% |
+276,714
| New | +$6.88M |
|
19
Rigel Pharmaceuticals
RIGL
$695M
| $7.2M | 1.75% |
201,629
-10,170
| -5% | -$279K |
|
20
Tandem Diabetes Care
TNDM
$1.13B
| $7.02M | 1.71% |
+55,599
| New | +$7.23M |
|
|
CORI
21
DELISTED
Corium International, Inc.
CORI
| $6.65M | 1.62% |
1,014,820
+2,400
| +0.2% | +$16.4K |
|
|
FOMX
22
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
| $5.26M | 1.28% |
568,549
+55,900
| +11% | +$500K |
|
|
ACT.PRA
23
DELISTED
ACTAVIS PLC Pfd Conv Ser A (Irl)
ACT.PRA
| $4.96M | 1.21% |
+4,900
| New | +$5.13M |
|
24
Enanta Pharmaceuticals
ENTA
$377M
| $4.72M | 1.15% |
154,300
+110,183
| +250% | +$4.29M |
|
|
AVDL
25
DELISTED
Avadel Pharmaceuticals
AVDL
| $4.05M | 0.99% |
+225,351
| New | +$3.53M |
|
Similar funds
BCP
PRHC
NAM
GG
SM
BC
SCPM
FAM
Senzar Asset Management's Q1 2015 Portfolio in Review
As of Q1 2015, Senzar Asset Management held 47 positions worth $410M, up 20% from $341M the previous quarter. Its ten largest holdings account for 65% of the portfolio.
Senzar Asset Management deployed $36M of net new capital in Q1 2015, opening 15 new positions and adding to 13 existing holdings. Its largest new stake was St Jude Medical: 733,600 shares worth $48M.
By sector, the portfolio is most concentrated in Healthcare at 83% of assets, down from 86% a quarter earlier.
On the sell side, the largest reduction was Sanofi, an estimated $10.8M trimmed.
- Senzar Asset Management's largest Q1 2015 buy was St Jude Medical: 733,600 shares worth $48M.
- Senzar Asset Management added most to Teva Pharmaceuticals in Q1 2015, an estimated $18.6M increase.
- Senzar Asset Management's biggest Q1 2015 reduction was Sanofi, cutting an estimated $10.8M.
- Senzar Asset Management fully exited Viatris in Q1 2015, selling an estimated $26.1M.
- Senzar Asset Management's ten largest holdings make up 65% of its $410M portfolio in Q1 2015.
- Senzar Asset Management opened 15 new positions and closed 14 in Q1 2015.
- Senzar Asset Management's portfolio value rose 20% quarter-over-quarter to $410M.
Based on Senzar Asset Management's 13F filing for Q1 2015, filed 15 May 2015.